Navigation Links
Adventrx Announces Positive Data From Multidrug Therapy With,CoFactor

ly significantly less (p < 0.05) than mice treated with either capecitabine alone (461.0 mm3 +/- 50.4) or mice treated with LV, 5-FU and capecitabine (447.8 mm3 +/- 46.5). Consistent with superior inhibition of tumor growth, treatment with CoFactor, 5-FU and capecitabine also prolonged survival compared to the other treatment regimens. The median survival of CoFactor, 5-FU and capecitabine treated mice (60 days) was statistically significantly longer (p < 0.05) than capecitabine alone (38 days) and LV, 5-FU and capecitabine (39 days). Importantly, the increased tumor inhibition and survival benefits of treatment with CoFactor, 5-FU and capecitabine did not come at the cost of added toxicity. Treatment with CoFactor, 5-FU and capecitabine caused less severe weight loss than all other drug treatments, including capecitabine alone. These results suggest a hybrid treatment regimen, consisting of a CoFactor and 5-FU treatment backbone coupled with capecitabine, might confer improvements in antitumor activity and survival without corresponding increases in systemic toxicity in patients with colorectal cancer. The Company plans to pursue further testing of this CoFactor treatment regimen.

About CoFactor

CoFactor (ANX-510) is a folate-based biomodulator drug designed to replace leucovorin as the preferred method to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy 5-fluorouracil (5-FU). In comparison to leucovorin, CoFactor creates more stable binding of the active form of 5-FU to the target enzyme, thymidylate synthase (TS). CoFactor bypasses the metabolic pathway required by leucovorin to deliver the active form of folate, allowing 5-FU to work more effectively. CoFactor is in Phase 3 and Phase 2b clinical trials for the treatment of metastatic colorectal cancer, as well as in a Phase 2 clinical trial for the treatment of advanced breast cancer.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:3/5/2015)... , March 5, 2015  Medical Diagnostic ... specializes in high complexity, state-of-the-art, automated DNA-based molecular ... Human Papillomavirus (HPV) testing which utilizes cutting edge ... Each year, approximately 12,000 women are diagnosed ... States . Genital Human Papillomaviruses (HPV) are ...
(Date:3/5/2015)... , March 5, 2015  Relmada Therapeutics, ... therapies for the treatment of chronic pain, today ... researchers to advisory roles. The panel of experts ... programs and efforts to advance the company pipeline ... They bring expertise in a range of areas ...
(Date:3/5/2015)... 5, 2015  Celsion Corporation (NASDAQ: ... host a conference call to discuss year-end 2014 ... development programs for ThermoDox®, its proprietary heat-activated liposomal ... platforms, TheraPlas™ and TheraSilence™, in immunotherapy and RNA ... 12, 2015. To participate in the call, interested ...
Breaking Medicine Technology:Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 2Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 2Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 4Celsion Corporation to Hold Year-End 2014 Financial Results Conference Call on Thursday, March 12, 2015 2
... May 13 NicOx S.A.,(Eurolist: COX) today announced ... in a series of planned clinical studies, in ... agreement to,develop new nitric oxide-donating antihypertensive agents using ... selected from,the companies, joint research program, of which ...
... study opens way for high-power permanent version of the glasses ... ... Innovative prism glasses can,significantly improve the vision and the daily lives ... in both eyes. The,peripheral prism glasses, which were invented by Dr. ...
Cached Medicine Technology:NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc. 2NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc. 3Prism Glasses Expand the View for Patients with Hemianopia 2Prism Glasses Expand the View for Patients with Hemianopia 3
(Date:3/6/2015)... Dr. Amy Reed, who together with her husband, ... use of power morcellators ( http://www.morcellatorlawsuit2015.com ) in uterine ... the launch of their public health campaign. The couple told ... mother of six had recently undergone surgery to remove a ... Reed had been in remission for about a year after ...
(Date:3/6/2015)... Greenwood Village, CO (PRWEB) March 06, 2015 ... reducing infant mortality around the world is traveling to ... meet with survivors of their malnutrition program. , This ... the same region in Angola, demonstrating their commitment to ... five and under. The team will engage with the ...
(Date:3/6/2015)... 2015 Follow us on LinkedIn ... and crowns, abutments and dentures are used to provide ... teeth and missing teeth. The growth in the global ... by an aging global population, expanding number of edentulous ... the 65+ population being edentulous or completely toothless, there ...
(Date:3/6/2015)... 06, 2015 US Sports Football Camps ... camps – two non-contact specialty camps and one contact ... Perfect Performance Training, located at Bowie State University and ... position specific skills, speed and strength of football athletes. ... University with Marvin Graves, former quarterback in the Canadian ...
(Date:3/6/2015)... 2015 Since Medicare began paying for ... has been an overwhelming demand from providers for straightforward ... CCM program. The Centers for Medicare & Medicaid ... , PYA’s updated white paper—“ Providing and Billing Medicare ... a detailed, yet practical “how to” manual for providers ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Comments on Report that Physician Working to Ban Uterine Morcellation Has Cancer Recurrence 2Health News:Power Morcellator News: Bernstein Liebhard LLP Comments on Report that Physician Working to Ban Uterine Morcellation Has Cancer Recurrence 3Health News:Power Morcellator News: Bernstein Liebhard LLP Comments on Report that Physician Working to Ban Uterine Morcellation Has Cancer Recurrence 4Health News:Saving Moses Returns to Angola to Continue Giving Infants and Children a Chance to Live 2Health News:Aging Population & Emphasis on Dental Care Drives the Dental Prosthetic & Implant Consumables Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Aging Population & Emphasis on Dental Care Drives the Dental Prosthetic & Implant Consumables Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Updated PYA White Paper Meets Demand for Guidance on Providing and Billing Medicare for Chronic Care Management 2
... , , Medtronic Featured as Official ... The American Association of Heart Failure Nurses (AAHFN) is ... February 8-14 .   , The purpose of Heart Failure Awareness ... common and debilitating condition.  AAHFN will achieve this goal through the ...
... but effective treatment, experts say , FRIDAY, Feb. 5 ... can be killed by a type of bacteria that ... maggots to disinfect wounds (maggot debridement therapy) is standard ... dead tissue and ingest bacteria that are killed in ...
... responsible for ,pending epidemic, researchers say , FRIDAY, Feb. ... patients but can cause work-related injuries in surgeons, suggests ... Medicine researchers found that 87 percent of laparoscopic surgeons ... physical symptoms or discomfort. , "We face a pending ...
... NEW YORK , Feb. 5 Hospital for ... today announced its support of the Arthritis Foundation and Ad ... raise awareness of osteoarthritis, increase public health education and support ... our extensive clinical and research resources on raising awareness of ...
... , , BEIJING, CHINA , Feb. 5 ... attention to a certain previously released news announcements namely January 7 ... January 12,2010 , and January 22, 2010 . , These ... these events are now starting to crystallize and are beginning to transform ...
... more likely to misuse prescribed drugs, suffer flareups ... patients who use herbal remedies experience increased symptoms and ... Researchers followed 326 asthma patients for 33 months. Of ... and used prescribed inhaled corticosteroids (ICS) less often than ...
Cached Medicine News:Health News:AAHFN Promotes Heart Failure Awareness Week Through Webinar 2Health News:Wound-Healing Maggots Succumb to Deadly Bacteria 2Health News:HSS Supports Arthritis Foundation Focus on Raising National Awareness of Osteoarthritis 2Health News:HSS Supports Arthritis Foundation Focus on Raising National Awareness of Osteoarthritis 3Health News:HSS Supports Arthritis Foundation Focus on Raising National Awareness of Osteoarthritis 4Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 2Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 3Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 4Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 5Health News:Herbals Not the Answer for Asthma, Study Shows 2
... growing portfolio of OxiMax® monitors, the ... compact, affordable bedside monitor. Equipped with ... it offers reliable operation during challenging ... the complete family of innovative OxiMax ...
The Model 5305 is a hand-held, portable, lightweight pulse oximeter designed for spot checking. It has a NiCad rechargeable battery....
The Model 340 is intended for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring....
... Model 130 has expanded memory capabilities for overnight ... to retain oxygen saturation and pulse rate data, ... best suit your needs:, ,1. The Model ... information for a single patient, making the device ...
Medicine Products: